ABSTRACT Dengue fever is a vector-transmitted viral infection. Non-vectorial forms of transmission can occur through organ transplantation. We reviewed medical records of donors and recipients with suspected dengue in the first post-transplant week. We used serologic and molecular analysis to confirm the infection. Herein, we describe four cases of dengue virus transmission through solid organ transplantation. The recipients had positive serology and RT-PCR. Infection in donors was detected through serology. All cases presented with fever within the first week after transplantation. There were no fatal cases. After these cases, we implemented dengue screening with NS1 antigen detection in donors during dengue outbreaks, and no new cases were detected. In the literature review, additional cases had been published through August 2017. Transmission of Dengue virus can occur through organ donation. In endemic regions, it is important to suspect and screen for dengue in febrile and thrombocytopenic recipients in the postoperative period.

Introducción: Los inhibidores de glicoproteína IIb/IIIa reducen los eventos cardiovasculares mayores adversos (MACE) en pacientes con síndrome coronario agudo. Objetivos: Determinar la incidencia de MACE y desenlaces de seguridad en pacientes con síndrome coronario agudo llevados a intervención percutánea coronaria primaria y administración intracoronaria e intravenosa de tirofiban comparado con una población donde no se administró dicho medicamento. Materiales y métodos: Cohorte prospectiva. Se incluyeron adultos con síndrome coronario agudo desde enero de 2010 hasta diciembre de 2012. Se realizó un modelo de riesgos proporcionales a un mes de seguimiento donde se evaluó el riesgo de MACE siendo la variable de interés el uso de tirofiban intracoronario e intravenoso. Resultados: Se incluyeron 382 pacientes. Un 46% (174 pacientes) recibieron tirofiban intracoronario. El promedio de edad fue 65 años vs. 60 años en los que no recibieron tirofiban (p = 0,00). La tasa de incidencia de MACE a un mes de seguimiento fue 13/1000 eventos y 15/1000 eventos entre los que recibieron y no tirofiban respectivamente (Logrank test = 0,935). El uso de tirofiban no se relacionó con menor incidencia de MACE (HR 1,09 95% IC 0,72-1,65) ni con sangrado mayor a un mes de seguimiento (1,72% vs. 2,88% p = 0,456). Conclusiones: El uso de tirofiban intracoronario e intravenoso en pacientes con evento coronario agudo no se relacionó con menor incidencia de MACE ni eventos de sangrado en esta población, sin embargo, se deben tener en cuenta otras variables clínicas y de severidad del evento coronario no medidas que pudieron influir en los resultados.

Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome. Objective: To determine the major adverse cardiovascular events and safety of intracoronary and intravenous tirofiban in patients with acute coronary syndrome with percutaneous coronary intervention (PCI) compared to a group of patients without this medication. Material and methods:rospective cohort. Adults with acute coronary syndrome from January 2010 to December 2012 were included. A proportional hazard regression model after 1 month of follow up where the risk of MACE and the interest variable was intracoronary and intravenous tirofiban were assessed. Results: 382 patients were included. 46% (174 patients) received intracoronary tirofiban. The average age was 65 years vs. 60 years in the group of non-tirofiban users (p = 0.00). The rate of MACE at the first month was od 13/1000 events and 15/1000 events respectively in the group tirofiban and non-tirofiban (log rank test 0,935). The tirofiban use was neither related to a lower incidence of MACE (HR 1.09 95% IC 0.72 1.65) nor to major bleeding after the first month of follow up (1.72% vs. 2.88% respectively, p = 0.456). Conclusions: Intracoronary and intravenous tirofiban in patients with acute coronary syndrome was neither related to lower incidence of MACE nor to bleeding events; however, it should be taken into account that other clinical variables and the severity of unquantified coronary events might influence the results.